Otcenásek M, Buchta V
Biofarmaceutický výzkumný ústav, spolecné pracovistĕ Ustavu experimentální biofarmacie AVCR.
Cesk Epidemiol Mikrobiol Imunol. 1993 Mar;42(1):29-34.
The authors tried to standardize the method of assessment of the minimal inhibitory concentration (MIC) of antimycotics for the evaluation of the sensitivity of opportunistic causal agents of mycoses. They paid attention to factors which cause deterioration of the reproducibility of tests and lead to intra- and interlaboratory variability of results. In conjunction with this the authors drew attention to the lack of uniformity of views on the application of these tests in clinical practice. In the author's view the reservation pertaining in particular to an inadequate correlation of results in vitro and in vivo do not cast doubts on the expedience of laboratory assessment of sensitivity. Testing of systemic antimycotics with a low pharmacotherapeutic index and a relatively high frequency of secondary resistance is particularly justified. In those instances assessment of MIC values is a significant component of monitoring of adequate antifungal chemotherapy, in particular when antimycotics are administered for prolonged periods to patients with altered immunity.
作者试图规范抗真菌药物最低抑菌浓度(MIC)的评估方法,以评价真菌病机会致病菌的敏感性。他们关注了导致试验重复性变差并引起实验室内和实验室间结果差异的因素。与此同时,作者还注意到对于这些试验在临床实践中的应用缺乏统一的观点。作者认为,特别是关于体外和体内结果相关性不足的保留意见,并不质疑实验室敏感性评估的合理性。对具有低药物治疗指数和相对较高继发耐药频率的全身性抗真菌药物进行检测尤其合理。在这些情况下,MIC值的评估是监测充分抗真菌化疗的重要组成部分,特别是当抗真菌药物长期用于免疫功能改变的患者时。